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Bernd Holleczek1,2* and Hermann Brenner1,3Abstract
Background: Studies on the implementation of Clinical Practice Guidelines (CPG) and particularly its effect on
breast cancer (BRC) survival on a population-level are scant. This population-based high resolution study from
Germany aims at providing data on the usage of BRC treatment, the extent of adherence to CPG and, as a novelty,
survival of BRC patients according to major recommended treatment options.
Methods: Data from the Saarland Cancer Registry including women diagnosed with invasive BRC without distant
metastasis and followed up between 2000 and 2009 were used. Provision of cancer care according to major
treatment options is presented by age, clinical subtypes of BRC, and over time. Conventional and modeled period
analysis was used to derive estimates of most up-to-date 5-year relative survival (RS) and the effect of non-adherence
to CPG on relative excess risk of death (RER).
Results: The study revealed increasing guideline adherence, with high levels already seen for local treatment
(e.g. 67% of the BRC patients in 2008/09 received breast conserving surgery), and substantial progress since the
millennium change with regard to sentinel node dissection (SND) and adjuvant systemic treatments (e.g. SND
and chemotherapy provided to 62% of all patients and 79% of the patients with nodal positive or hormone
receptor negative BRC in 2008/09, respectively). It further demonstrated increased cancer related mortality
among patients without guideline compliant cancer treatment (e.g. patients with nodal positive and hormone
receptor negative BRC who were not treated with chemotherapy had a 5-year RS of 29% (RER: 2.89, 95% CI: 1.46–5.71)
compared to 54% for patients obtaining chemotherapy).
Conclusions: This study provides data on the implementation of CPG in a highly developed European country and
extends available population-based survival data of BRC patients and may provide evidence of increased cancer
related excess mortality, if BRC patients do not receive guideline compatible treatment.
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Invasive breast cancer (BRC) is the most frequent cancer
among women worldwide [1], with estimated 72,000
new cases and 17,200 deaths in Germany in 2008 [2].
Within the past two decades, BRC mortality has steadily
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article, unless otherwise stated.increased early detection [3,4]. However, there is on-
going research and controversy with regard to the pos-
sible size of the effect of early detection and organized
mammography screening programs in developed coun-
tries [5-9].
Population-based survival studies of BRC patients with
regard to delivered treatment according to available
Clinical Practice Guidelines (GPG) are scant. In the past,
population-based data on long-term survival of BRC pa-
tients have commonly been restricted to overall esti-
mates or provided estimates with regard to age, tumord Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Clinicians, patients, researchers and health care planners
are in great need for unselected survival data, which
may present – along with data on the actual usage of
cancer specific treatments – an “overall” picture of can-
cer related excess mortality according to cancer treat-
ment options, and provide important information on the
effectiveness of cancer care in the community setting.
Survival studies using available routine data from
population-based cancer registries are intrinsically diffi-
cult to interpret with regard to effects of early detection
and postponement of death of the patients due to effect-
ive treatment, as these registries commonly collect only
very basic information items only (e.g. sex of the patient,
cancer site, date of diagnosis, summary stage, tumor
morphology, and follow-up of the patient) [16,17]. As a
prerequisite for explaining observed survival differences
with regard to effects from early detection and cancer
treatment, population-based cancer registries need to
additionally collect detailed information on the stage
at diagnosis, the diagnostic workup and administered
treatment of the patients. Survival studies which are
based on such extended data are often termed as ‘high
resolution’ studies [16].
This high resolution study from Germany aims at pro-
viding population-based data on the extent and variation
of the delivery of BRC treatment and adherence to avail-
able CPG in a highly developed European country. It
further extends a previously published study with de-
tailed cancer survival by cancer characteristics for clin-
ical subgroups of patients [15] and provides survival of
BRC patients with regard to the effect of non-adherence
to CPG on cancer related mortality on a population-
level within the calendar period 2000–2009.
Methods
This study used data from the Saarland Cancer Registry,
which covers the federal state of Saarland in South-
Western Germany with a population of approximately
1.02 million inhabitants in 2009 (constituting 1.3% of the
national population). The registry collects information on
invasive and in situ neoplasms since 1968 and obtains
notifications from hospitals, radiotherapy departments,
pathology laboratories, screening programs and general
practitioners. The proportion of the registered incident
cancer cases is regularly estimated to be >95% [2,18].
The study included 8571 female patients with an inva-
sive BRC (ICD-10: C50) diagnosed between 2000 and
2009 and aged ≥15 years. Patients with a previous inva-
sive BRC were not included. Mortality follow-up was
based on death certificates and linkage of patients with
central population registries (see [15] for details). In
addition to routinely collected tumor information, data
on further tumor characteristics (such as HR status, orHER2/neu expression) and cancer treatment were ob-
tained by means of requested additional reports and data
collection at source by registry staff based on a standard-
ized extraction protocol (see [15] for details). Standard
procedures of quality control of the registry were applied
with respect to accuracy, completeness and consistency of
the extended data [19]. For patients diagnosed with a bilat-
eral BRC, tumor and treatment data of the more advanced
tumor were included into the study database.
For the analyses, three age categories were used: 15–49,
50–69 and ≥70 years. The European Network of Cancer
Registries recommendations were used to classify tumor
stage as “localized” (T1-3N0M0), “regionally or locally
advanced” (T1-3 N +M0, T4M0), “distant metastasis”
(M1), or “missing” [20]. Histologic grade included the
categories “low”, “intermediate”, “high”, and “missing” ac-
cording to the WHO scheme. HR status was classified as
“positive” (both estrogen and progesterone receptor posi-
tive), “mixed” (either estrogen or progesterone receptor
positive), “negative” (both estrogen and progesterone re-
ceptor negative), and “missing”. The categories of HER2/
neu expression were “positive” (including borderline),
“negative”, and “missing”.
The currently available German national CPG on the
treatment of BRC [21], which differ only marginally from
guidelines from other countries [22], recommend breast
conserving surgery (BCS) followed by radiotherapy or
mastectomy alone for effective local treatment of early
stage BRC or mastectomy and radiotherapy for locally
advanced tumors. Dissection of lymph nodes (preferably
sentinel node dissection) is required for proper staging.
Adjuvant systemic treatment aims at preventing tumor re-
currence and includes chemotherapy according to stage
and risk of recurrence, antiestrogen treatment for patients
with hormone receptor (HR) positive or mixed tumors,
and monoclonal antibodies (trastuzumab) if a carcinoma
shows HER2/neu expression. In case of advanced disease,
systemic treatment is recommended prior to surgery.
Elderly patients should receive an adjuvant systemic treat-
ment comparable to younger patients, taking into account
altered organ functions and comorbidity.
For local surgery, the categories “BCS” including lump-
ectomy and quadrantectomy, “mastectomy”, “none”, and
“missing” were used. Dissection of lymph nodes was either
categorized as “axillary lymph node dissection” (ALND),
“sentinel node dissection” (SND), “ALND after SND”,
“none”, and “missing”. To categorize the delivery of adju-
vant radiotherapy and systemic treatments, the categories
“yes”, “none”, and “missing” were used.
The following major treatment options according to
the national CPG [21] were evaluated with regard to the
provision to and the survival of the BRC patients with-
out distant metastases: local treatment consisting of (i)
either BCS and radiotherapy or mastectomy alone in
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followed by radiotherapy in patients with T1/T2N + tu-
mors, (iii) combination of mastectomy and radiotherapy
in patients with T3/T4 tumors, (iv) dissection of lymph
nodes (SND, ALND after SND and ALND), and systemic
treatment consisting of (v) chemotherapy in patients
with nodal positive or HR negative BRC, (vi) antiestro-
gen treatment in patients with HR positive or mixed
tumors, and (vii) trastuzumab given to patients with
HER2/neu expressed tumors.
Univariate description of the patients and tumor
characteristics was derived for the calendar intervals
2000–2004 and 2005–2009. The provision of cancer care
by age and temporal trends was analyzed for the calen-
dar intervals 2005–2009 and 2000–2009, respectively.
Relative survival (RS), which quantifies excess mortal-
ity due to the cancer and captures both direct and indir-
ect mortality is derived as ratio of observed survival of
the cancer patients to expected survival of a group of
sex-, age- and calendar time of observation-matched in-
dividuals with average risk of death from all causes from
the source population [23]. The Ederer II method was
used for deriving expected survival estimates [24]. Details
on the generation of the used life tables may be found
elsewhere [25].
Period analysis methods were used to obtain up-to-date
estimates of 5-year RS. Classical cohort based survival esti-
mates may reflect possible recent progress in cancer care to
a very limited extent only and thus lag behind the expected
survival of most recently diagnosed cancer patients [26,27].
Period analysis uses survival experience observed in a speci-
fied calendar period (typically, the most recent period with
available incidence and mortality follow-up information),
and, in addition to right censoring, survival observations
are left truncated at the beginning of the calendar period
(e.g. a period estimate of 5-year survival derived for the cal-
endar period 2005–2009 may include patients diagnosed
between 2000 (at the earliest) and 2009, and therefore, the
number of patients contributing survival experience to a
period estimate differs from the number of subjects diag-
nosed in the respective calendar period) [28].
Period estimates of 5-year RS of patients were derived
by age, tumor characteristics, and recommended local
and systemic cancer treatment. Patients without follow-
up information and with death certificate only (DCO)
notified tumors were excluded from the survival ana-
lyses. Standard errors are based on Greenwood’s method
[29]. Age standardized survival was derived as weighted
average of age group-specific survival according to the
International Cancer Survival Standards (ICSS) [30].
Model-based period analysis was used as previously
described to quantify relative excess risks of death (RER)
and for statistical significance testing [31,32]. Based on
an additive hazards model, RER quantifies the relativecancer related excess mortality between the specific “ex-
posed” groups of cancer patients (defined by age, stage,
other characteristics, or cancer treatment) compared to
the “unexposed” reference group of matched persons
from the general population [33,34]. The models to in-
vestigate the effect of guideline adherence on 5-year RS
and RER for different groups of patients with regard to
tumor characteristics and treatment options included
the information, whether a patient received the investi-
gated treatment (e.g. antiestrogen treatment in patients
with HR positive or mixed tumors) as dichotomous vari-
able and adjusted for age, T, N, histologic grade, hormone
receptor status and HER2/neu expression (explanatory
variables of categorical type). For the RER estimates, 95%
confidence intervals (CI) were derived. The reported
p-values are based on Wald tests (based on an asymptotic
Chi-squared statistic) for inclusion of the respective
variables into the models.
The R Language and Environment for Statistical
Computing (release 2.11.1) [35] and the “periodR” pack-
age (release 1.0-6) were used for the data preparation,
survival estimation and modeling [36,37].
The data used for this study were collected by the
Saarland Cancer Registry according to state legislation
for the purpose of monitoring cancer care and outcomes
and the anonymized data were used according to the re-
spective provisions for the use of research data.
Results
Table 1 shows characteristics of the included 8571 patients
and their tumors. In 2005–2009, the patients were on aver-
age 63.3 years old at diagnosis, 56% had a tumor which was
2 cm or larger, 44% presented with positive lymph nodes
and 9% with distant metastases. Most frequently, tumors
were of intermediate grade (68%), HR positive (72%) and
HER2/neu negative (76%). Almost all tumors were micro-
scopically confirmed. Follow-up was available for virtually
all patients and 2% of the tumors were notified by a death
certificate only. Overall, very similar characteristics were
seen for patients diagnosed in 2000–2004 and 2005–2009.
Provision of local treatment, lymph node dissection
and adjuvant systemic treatment to BRC patients pre-
senting without distant metastases and who were diag-
nosed between 2005 and 2009 is shown in Table 2.
Information on local treatment and lymph node dissec-
tion was available for about 76% of the patients. BCS
with or without radiotherapy was given to 57% and 10%
of the patients. Overall, 14% and 18% of the patients
underwent a mastectomy with or without radiotherapy,
respectively. Staging was based on SND, ALND after
SND and ALND for 37%, 17% and 42% of the patients
respectively. Almost all patients received local surgery
and dissection of lymph nodes (the proportions of pa-
tients without such treatment were below 2% each).
Table 1 Characteristics of female breast cancer patients (ICD-10: C50) from Saarland diagnosed between 2000 and 2009
Characteristic Category 2000-2004 2005-2009
n % n %
Overall 4147 4424
Age 15-49 years 754 18.2 785 17.7
50-69 years 1973 47.6 2098 47.4
> = 70 years 1420 34.2 1541 34.8
T Available 3880 93.6 3951 89.3
1a 1671 43.1 1742 44.1
2a 1574 40.6 1633 41.3
3a 206 5.3 247 6.3
4a 429 11.1 329 8.3
N Available 3483 84.0 3650 82.5
0a 1964 56.4 2057 56.4
1a 1159 33.3 1017 27.9
2a 273 7.8 345 9.5
3a 87 2.5 231 6.3
M Available 3458 83.4 3222 72.8
0a 3129 90.5 2923 90.7
1a 329 9.5 299 9.3
Microscopic confirmation 4031 97.2 4312 97.5
Histologic grade Available 3856 93.0 4201 95.0
Lowa 277 7.2 304 7.2
Intermediatea 2273 58.9 2872 68.4
Higha 1306 33.9 1025 24.4
Hormone receptor status Available 3620 87.3 3720 84.1
Positive (ER + PgR+)a 2474 68.3 2688 72.3
Mixed (ER + or PgR+)a 531 14.7 451 12.1
Negative (ER- PgR-)a 615 17.0 581 15.6
HER2/neu expression Available 2505 60.4 3598 81.3
Positivea,b 625 25.0 866 24.1
Negativea 1880 75.0 2732 75.9
Death certificate only notified 67 1.6 100 2.3
No follow-up available 79 1.9 48 1.1
ER: estrogen receptor; PgR: progesterone receptor; a) proportions among patients with available information; b) including 401 tumors with borderline expression;
the table is based on previously published data [15].
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negative tumors, HR positive or mixed tumors or HER2/
neu expressed BRC, 77% received chemotherapy, 91% an
antiestrogen treatment and 42% a targeted therapy, re-
spectively. Comparison by age showed, that BRC pa-
tients aged ≥70 years received BCS with radiotherapy
less often and mastectomy more often than younger pa-
tients (39% vs. 65% and 45% vs. 26%, respectively). SND
was performed less often among elderly patients, too
(43% vs. 60%). Likewise, the usage of chemotherapy
and trastuzumab was higher among younger patients
(91% vs. 40% and 51% vs. 20%, respectively). By contrast,antiestrogen treatment was quite similar in both age
groups (92% and 89%, respectively).
Figure 1 depicts time trends of the provision of major
treatment options to BRC patients without distant me-
tastases diagnosed between 2000 and 2009. During the
study period, the usage of BCS increased from 59% in
2000/01 to 67% in 2008/09, whereas the proportion of
patients with mastectomy dropped for about the same
amount. Simultaneous to the tremendous rise of the
usage of SND to 62%, the usage of ALND dropped from
91% to 33%. Chemotherapy usage among nodal positive
or HR negative BRC patients increased from 60% to
Table 2 Provision of cancer care to breast cancer patients without distant metastasis by age
Treatment Category Overall 15-69 years > = 70 years
N % N % N %
Overall 4025 2691 1334
Local treatment Available 3038 75.5 2078 77.2 960 72.0
BCSa 316 10.4 187 9.0 129 13.4
BCS + radiotherapya 1716 56.5 1342 64.6 374 39.0
Mastectomya 558 18.4 262 12.6 296 30.8
Mastectomy + radiotherapya 424 14.0 284 13.7 140 14.6
No surgerya 24 0.8 3 0.1 21 2.2
Lymph node dissection Available 3043 75.6 2145 79.7 898 67.3
ALNDa 1274 41.9 812 37.9 462 51.4
SNDa 1139 37.4 849 39.6 290 32.3
SND + ALNDa 525 17.3 432 20.1 93 10.4
Nonea 47 1.5 7 0.3 40 4.5
Chemotherapyb Available 1571 86.2 1154 91.4 417 74.5
Yesa 1215 77.3 1050 91.0 165 39.6
Nonea 356 22.7 104 9.0 252 60.4
Antiestrogen treatmentc Available 2232 75.8 1556 80.0 676 67.6
Yesa 2035 91.2 1433 92.1 602 89.1
Nonea 197 8.8 123 7.9 73 10.9
Targeted therapyd Available 443 55.7 325 58.9 118 48.4
Yesa 188 42.4 164 50.5 24 20.3
Nonea 255 57.6 161 49.5 94 79.7
Local treatment, lymph node dissection and adjuvant systemic treatment of female BRC patients without distant metastases (ICD-10: C50) from Saarland
diagnosed between 2005 and 2009. BCS: breast conserving surgery; ALND: axillary lymph node dissection; SND: sentinel node dissection; a) proportions among
patients with available information; b) among patients with positive lymph nodes or hormone receptor negative tumors; c) among patients with hormone
receptor positive or mixed tumors; d) among patients with HER2/neu expressed tumors; patients presenting with distant metastases or DCO notified tumors
were excluded.
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with HR positive or mixed tumors rose from 79% to
93%, and the proportion of patients with HER2/neu
positive tumors who were given trastuzumab rose to
47% in 2008/09.
Table 3 presents 5-year RS in 2005–2009 by age and
tumor characteristics. Overall age standardized 5-year RS
was 83%. Survival of patients aged 70 years or older was
substantially lower than survival observed for younger pa-
tients (survival was 89%, 88% and 77% for patients aged
15–49, 50–69, and ≥70 years, respectively). Five-year RS of
patients with localized, locally/regionally advanced and me-
tastasized BRC was 99%, 80%, and 23%. Survival further
decreased with increasing grade (survival was 102%, 87%
and 73%, for patients with low, intermediate and high grade
tumors, respectively). Patients with HR positive or mixed
tumors had a substantially higher survival (89% and 83%,
respectively) compared to those patients with HR negative
tumors (65%). If tumors showed HER2/neu expression, the
patients’ survival was lower compared to patients with
HER2/neu negative tumors (79% and 86%, respectively).Table 4 presents 5-year RS of BRC patients without
distant metastases by age, tumor stage and local treat-
ment. Five-year RS of patients receiving BCS without
radiotherapy was 84%, whereas almost no decreased sur-
vival was observed for BRC patients receiving radiother-
apy. Patients with mastectomy and mastectomy with
radiotherapy had a 5-year RS of 88% and 78%, respect-
ively. Patients without surgery had a 5-year RS of 41%
only. For patients with localized T1/T2 tumors receiving
a BCS followed by radiotherapy or mastectomy alone al-
most no decrease in 5-year RS was observed. Those with
T1/T2 tumors with positive lymph nodes who received
either BCS or mastectomy and additional radiotherapy
had a 5-year RS of 90%. Five-year RS of patients with
T3/T4 tumors who received mastectomy and radiother-
apy was 89% if having clear lymph nodes compared to
74%, if having positive lymph nodes.
Table 5 shows 5-year RS and RER of BRC patients
without distant metastases by age, tumor characteristics,
and major systemic treatment options. Patients with
nodal positive and HR positive or mixed tumors who did
Figure 1 Trends of the provision of cancer treatment between 2000 and 2009. Trends of the provision of local treatment (a), dissection of
lymph nodes (b) and adjuvant systemic treatment (chemotherapy among patients with nodal positive or hormone receptor negative tumors;
antiestrogen treatment among patients with hormone receptor positive or mixed tumors; trastuzumab among patients with HER2/neu expressed
tumors; c) among female breast cancer patients without distant metastases (ICD-10: C50) from Saarland diagnosed between 2000 and 2009.
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had an age-standardized 5-year RS of 86% (RER 1.45;
95% CI: 0.78-2.68) compared to 99% for those who did.
This survival difference was much more pronounced
among patients aged ≥70 years than younger patients.
Patients with positive lymph nodes but HR negative tu-
mors who did not receive chemotherapy had a 5-year RS
of 29% (2.89; 1.46-5.71) compared to 54% for patients
obtaining chemotherapy.
Survival of patients with nodal negative and HR nega-
tive tumors who did not receive chemotherapy was 84%
(0.80, 0.20-3.18) compared to 95% if they underwent
chemotherapy. Patients with HR positive or mixed tu-
mors without antiestrogen treatment had a 5-year RS of
86% (1.75; 0.99-3.07) compared to 97% if such treatment
was administered. The analysis of age specific 5-year RS
of these patients showed a much higher survival differ-
ence in patients aged > =70 years, if they received no an-
tiestrogen treatment (minus 14% units), than in younger
patients (minus 8% units). Patients with HER2/neu
expressed tumors who received no targeted therapy had
a 5-year RS of 84% (2.17; 0.91-5.14) compared to 89% if
trastuzumab was provided.
Discussion
As a novelty, this study presents provision of cancer
treatment and up-to-date survival of patients with non-metastasized BRC on a population level according to
age, clinical subgroups, and major treatment options.
The study revealed increasing adherence to CPG be-
tween 2000 and 2009, e.g. rises in the usage of BCS,
chemotherapy and antiestrogen treatment and the intro-
duction of SND for staging and use of trastuzumab in
patients with HER2/neu expressed tumors. The analyses
further demonstrated major disparities in the provision
of cancer treatment by age.
The extent of adherence to CPG and the observed
trends during the study period corresponded to findings
from previous population-based studies from other
Western countries (e.g. proportion of patients with BCS
receiving radiotherapy: Saarland 2004/05: 85%, region of
Piedmont (Italy) 2004: 88%, Canadian regions 2000–2004:
ranging between 77% and 83%; chemotherapy in nodal
positive patients: Saarland: 73%, region of Piedmont: 64%,
Canadian regions: between 53%-68%; antiestrogen treat-
ment in HR positive or mixed patients: Saarland 2000/
2001: 79%, Canadian regions: 79%-85%) [38-41].
Compared to data from other studies including patients
diagnosed prior to the millennium change, the observed
proportions of guideline adherence were comparable or
higher [42-47]. Previous studies from Germany on the ex-
tent of guideline adherence were based on a cohort study
[48] or included hospital cohorts [42,43,49] and provided
somewhat higher levels of guideline adherence and, along
Table 3 Five year relative survival of female breast cancer
patients by age and tumor characteristics
Characteristic Category N RSa SE
Overall 7622 83.2 0.9
Age 15-49 years 1424 89.1 1.2
50-69 years 3761 88.0 0.9
> = 70 years 2437 76.7 1.8
Stage Localized 3488 99.2 1.3
Localized; T1 2110 104.9 1.6
Localized; T2 1254 92.7 2.1







Distant metastasis 414 23.1 2.8
Missing 1032 81.7 2.1
Histologic gradeb Low 543 102.0 3.2
Intermediate 4829 86.7 1.1
High 2013 73.3 1.8
Missing 221 65.0 5.0
Hormone receptor
statusb
Positive 4824 88.6 1.1
Mixed 862 83.3 2.7
Negative 1034 65.0 2.6
Missing 886 77.7 2.7
HER2/neu expressionb Negative 4345 86.3 1.2
Positive 1374 79.4 2.2
Missing 1887 79.8 1.9
Five year RS of female breast cancer patients (ICD-10: C50) from Saarland
estimated for the calendar period 2005–2009 by age and tumor characteristics. N:
number of patients contributing survival experience; RS: point estimate of 5-year
relative survival; SE: standard error of RS; a) except for age group-specific survival
estimates, age standardized estimates of 5-year RS were derived using the ICSS
weights; b) cases without microscopic verification were excluded.
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characteristics nominally higher survival estimates.
The implementation of specialized breast centers in
Germany that aim at the implementation of evidence- and
consensus-based CPG [50], which started in Saarland as
well as in Germany in 2004 [51], are well reflected in
the data. This particularly applies for the increased
usage of systemic treatments (e.g. usage of chemother-
apy in patients with nodal positive or HR negative
tumors or trastuzumab in patients with HER2/neu
expressed tumors increased by 19% units and 44%
units to 79% and 47%, respectively, between 2000/01
and 2008/09). Dramatic changes in axillary staging
could be observed after adoption of SND (usage 2000/
01: 1%. 2008/09: 62%), a development that started
somewhat earlier in the US [52].Like previous studies from other countries, this study
further demonstrated discrepancies in the adherence to
CPG in elderly patients [53-56]. Other factors influen-
cing provision of treatments include restricted access to
cancer care, doctors’ perceptions, level of evidence, and
patient preferences [57,58], but also race, health insur-
ance coverage, socio economic status and size of hospital
may influence the receipt of guideline concordant cancer
treatment [59].
Compared to other European or industrialized coun-
tries, Saarland ranks middle in terms of 5-year RS sur-
vival and its trends in the past [14,60-62]. Inferior
population-based survival of elderly patients has been
reported in many previous studies (e.g. [12,14,63,64]).
Two recent studies showed similar age- and stage-
stratified survival trends between Germany and the US
among younger patients, but pronounced differences for
elderly patients [65], or revealed inferior survival of eld-
erly BRC patients across all clinical subgroups [15]. In-
ferior survival of elderly patients is commonly explained
by comorbidity and differences in the delivery of cancer
care [56,66-69].
The analyses revealed inferior age standardized 5-year
RS and tentatively increased RER of death for patients
with nodal positive tumors, HR positive or mixed tu-
mors and HER2/neu expressed tumors, if the patients
did not receive recommended adjuvant chemotherapy
with or without antiestrogen treatment (RER 1.45 and
2.89; p-values: 0.239 and 0.002), antiestrogen treatment
(1.75; 0.053) and trastuzumab (2.17, 0.080). These results
are in line with findings from few previous studies using
cancer registry data [70] or data from hospital based co-
horts [71,72], although two recent registry-based studies
did not find an association between guideline compli-
ance and BRC survival [53,54].
Commonly, population-based cancer registries record
only a limited amount of data (such as age, tumor site,
summary stage and morphology) which are used as sur-
rogates for clinical information on tumor detection and
treatment of the patients [73]. Thus survival estimates
according to such surrogate information are representa-
tive for patients receiving “average” cancer care. The
data available for this work allowed detailed analyses ac-
cording to the actual provision of cancer treatment and
survival of the BRC patients. The derived survival data
then provide a quantitative measure of the effectiveness
of guideline adherent cancer care in the routine setting
and extend the data available from clinical trials. Often,
clinical trials do not provide fully representative data on
the effectiveness of cancer treatments due to selective
inclusion of trial enrollees (e.g. under-representation of
elderly patients) [74-76].
The study has several strengths. The completeness of
case ascertainment of the Saarland Cancer Registry is
Table 4 Five year relative survival of female breast cancer
patients by age, tumor stage and local treatment
Patient/tumor
characteristics
Treatment N RSa SE
All patients BCS 119 84.3 4.7
BCS + radiotherapy 3285 98.5 1.5
Mastectomy 613 87.7 2.9
mastectomy + radiotherapy 736 78.4 3.3
no surgery 43 40.8 6.7





































mastectomy + radiotherapy 55 88.7 12.9
T3/T4; nodal
positive
mastectomy + radiotherapy 256 73.6 5.1
Five year RS of female BRC patients (ICD-10: C50) from Saarland estimated for the
calendar period 2005–2009 by age, tumor stage and local treatment. N: number
of patients contributing survival experience; RS: point estimate of 5-year relative
survival; SE: standard error of RS; a) except for age group-specific survival, age
standardized estimates were derived using the ICSS weights; including patients
with microscopically verified tumors and available information on age and stage
and the respective local treatment; patients presenting with distant metastases or
DCO notified tumors were excluded.
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http://www.biomedcentral.com/1471-2407/14/757regularly estimated above 95% [2,18] and the registry
regularly contributes to national and international col-
laborations [2,62,77]. Follow-up information was avail-
able for virtually all patients. As almost all tumors were
microscopically, and as the used data were derived from
multiple sources (e.g. discharge letters, case summaries,
review of medical records at source by registry staff ), the
validity of tumor information and clinical data may be
considered as high. By using period analysis methodology,
most up-to-date estimates of cancer survival could be de-
rived. Period estimates closely predict cancer survival later
observed for patients diagnosed in the respective calendarperiod and allows early detection of changes in the long-
term survival of patients, which has been shown by exten-
sive empirical evaluation [28,78-80].
However, a number of important limitations must be
considered as well: first, even if the registry provided
detailed data that exceed the amount usually available
on a population level, the treatment information solely
included whether a specific treatment was provided or
not. Additional data on the start and end of a treatment,
the intent or a premature discontinuation were not
available. Neither was information available on comor-
bidity [81] and other factors, such as volume of health
care providers [82,83], or socio-economic status, [84-86]
which are associated with the delivery of cancer care or
disparities in cancer survival. It is therefore not possible
to quantify to what extent the apparent increase in mor-
tality associated with non-adherence to CPG is due to
specific reasons for non-adherence, such as contraindi-
cations resulting from comorbidity, patient preferences
or other reasons.
We used 5-year RS as a measure that corrects for mor-
tality from other causes of death (and thus is a measure
for net survival in the hypothetical situation, where BRC
was the only cause of death). However, when comparing
survival of BRC patients with regard to administered
cancer treatment, comorbidity may act as a confounder.
To address this issue (at least partly), adjustment for age
(by means of stratification of the analyses and by deriv-
ing age-standardized estimates of 5-year RS) was used as
information on comorbidity was not included in the
used data.
Second, information on tumor characteristics and can-
cer treatment were available for some four out of five
patients (e.g. HR status: 86%, local surgery: 77%, chemo-
therapy: 80%, antiestrogen treatment: 78%). Solely infor-
mation on targeted therapy was available for 59% of the
patients only. The extent of missing information and
the observational design of the study warrant caution
in the interpretation of the findings (which particularly
applies to the association between provision of cancer
treatment and outcome). For that reason, stratification of
the analyses and age adjustment were applied to account
(at least partly) for possible bias from exclusion of patients
due to missing data.
Third, for some variables (e.g. age or co-variables in
the modeled analyses) rather crude categories were used,
but this allowed best use of the available data. Due to
the distribution of clinical subtypes of BRC and the large
proportion of patients already treated according to CPG,
some strata were rather small and some of the derived
estimates of 5-year RS and RER had large standard
errors (>5% units) or p-values or age-specific analyses
were even not possible for some subgroups of patients
(e.g. patients with T3/T4 or HER2/neu positive tumors).
Table 5 Five year relative survival and relative excess risk of death of female breast cancer patients by tumor
characteristics, systemic treatment and age
Patient/tumor characteristics Treatment Provision N RSa SE RERb 95% CI p-value
Nodal positive tumor, ER + or PgR+ Chemotherapy + antiestrogen treatment yes 781 99.0 3.7 REF
no 506 86.2 3.1 1.45 0.78-2.68 0.239
Nodal positive tumor, ER + or PgR+,
age 15–69 years
Chemotherapy + antiestrogen treatment yes 701 92.0 1.8
no 264 88.3 3.0
Nodal positive tumor, ER + or PgR+,
age > =70 years
Chemotherapy + antiestrogen treatment yes 80 95.0 8.9
no 242 83.5 5.5
Nodal positive tumor, ER- and PgR- Chemotherapy yes 238 54.3 6.3 REF
no 30 28.5 9.7 2.89 1.46-5.71 0.002
Nodal negative tumor, ER- and PgR- Chemotherapy yes 310 94.9 5.5 REF
no 104 83.9 6.2 0.80 0.20-3.18 0.751
ER + or PgR+ Antiestrogen treatment yes 3663 97.1 1.3 REF
no 536 85.6 3.8 1.75 0.99-3.07 0.053
ER + or PgR+, age 15–69 years Antiestrogen treatment yes 2664 96.8 0.7
no 401 89.4 2.4
ER + or PgR+, age > =70 years Antiestrogen treatment yes 999 96.2 2.5
no 135 81.8 7.4
HER2/neu positive tumor Targeted therapy yes 198 89.3 9.5 REF
no 509 84.4 4.1 2.17 0.91-5.14 0.080
Five year relative survival and relative excess risk of death of female breast cancer patients (ICD-10: C50) from Saarland estimated for calendar period 2005–2009
by tumor characteristics, systemic treatment and age. N: number of patients contributing survival experience; RS: point estimate of 5-year relative survival; SE:
standard error of RS; RER: relative excess risk (of death); CI: confidence interval; a) except for age group-specific survival, age standardized estimates were derived
using the ICSS weights; b) adjusted for age (15–49, 50–69, > = 70 years), tumor size (<5 cm (T1/T2), > = 5 cm (T3/T4)), lymph node involvement (negative, N1,
N2/N3), histologic grade (G1/G2, G3/G4), hormone receptor status (ER + or PgR+, ER- and PgR-) and HER2/neu expression (positive, negative); including patients
with microscopically verified tumors and available information on age, T, N, histologic grade, hormone receptor status, HER2/neu expression and provision of the
respective systemic treatment; patients presenting with distant metastases or DCO notified tumors were excluded.
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lower survival and tentatively increased RER of death of
patients without guideline compatible local and adjuvant
systemic treatment. Here, an analysis based on a much
larger population would have allowed to extend the
resolution of the analyses and to derive estimates with
increased precision and would have increased the power
of the analyses.
Within the National Cancer Plan, the nationwide im-
plementation of hospital based cancer registries and the
development of necessary information structures link-
ing clinical information and data from population-
based cancer registries has been launched in Germany
in 2013 [87].
Currently, there is a time lag of about two and a half
years after a calendar year has ended until case ascer-
tainment and follow-up are sufficiently completed and
the data are available for reporting and further research
(this similarly applies to the Saarland Cancer Registry as
well as other population-based cancer registries). The
definition of specific episodes (e.g. tumor diagnosis, end
of a specific treatment, or recurrence of the disease) thattrigger a notification to the registry and the implementa-
tion of a common dataset for hospital based cancer
registries and information structures for linkage of clin-
ical data with population-based cancer registries will
help to reduce the aforementioned latency.
A common database including both data from
population-based cancer registries and data from
hospital based cancer registries (to be built up in
Germany in the years to come) will allow to use these
data not only for survival studies that largely extend
the possibilities presented in this study (e.g. providing
cancer survival data adjusted for comorbidity, or ana-
lyses with regard to other endpoints or late effects of
cancer treatment), but particularly for measuring the
provision of cancer care at a much higher level of detail
as a prerequisite to better understand the observed
gaps in the provision of cancer care and to take action
to overcome the observed survival deficits and in-
creased cancer related mortality among patients with
insufficient cancer care.
Even if Saarland constitutes only a small proportion of
the national German population, it is well representative
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available high quality data, the findings of the study may
nevertheless provide relevant evidence for clinicians and
their patients, researchers and health care planners on
BRC survival and cancer related mortality for Germany
at this stage.
Conclusions
Weighting up strengths and limitations, this study may
provide important and clinically relevant findings. It re-
veals increasing adherence to major recommended treat-
ment options, with high levels already observed for local
treatment and substantial progress within recent years
with regard to SND and adjuvant systemic treatment in
a highly developed European country. It further provides
population-based cancer survival for clinical subgroups
of patients with regard to treatment usage and – based
on the data available – demonstrated tentatively in-
creased cancer related excess mortality among BRC pa-
tients who did not receive guideline adherent treatment.
This study may thus provide relevant evidence for clini-
cians and their patients, researchers and health care
planners of the effect of non-adherence to CPG on can-
cer related survival on a population level.
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